Newest OncoKB updates: October 2, 2023

[Nissan, Moriah]

October 2, 2023 Data version: v4.9

 

• Updated therapeutic implications - Changed level of evidence

Gene	Mutation	Cancer Type	Drug(s)	Previous Level	Current Level	Reason
RET	Oncogenic Mutations	Medullary Thyroid Cancer (MTC)	Pralsetinib	1	3A	Withdrawal of FDA approval for Pralsetinib for RET-mutant MTC
ALK	Oncogenic Mutations	Non-Small Cell Lung Cancer	Lorlatinib	1	No level	Adherence to FDA drug label and CDx for Lorlatinib

 

• Updated therapeutic implications - Addition of therapies for variants with a level of evidence

Gene	Mutation	Cancer Type	Current Level of Evidence	Drug(s) currently in OncoKB™	Drug(s) added to OncoKB™	Evidence
Other Biomarkers	MSI-H	Endometrial Cancer	1	Pembrolizumab (All Solid Tumors)	Dostarlimab + Carboplatin + Paclitaxel (Level 1, Endometrial Cancer)	FDA-approval of Dostarlimab for MSI-H endometrial cancer; PMID: 36972026

 

• Addition of 11 new genes:

ELF4 ELK4 ELL ELN ERC1 FOXN4 HIRA ONECUT2 POU3F2 SF3B2 ZBTB7A

 

As always, don’t hesitate to reach out if you have comments, questions or suggestions. We love to hear from you.

 

--

 

The OncoKB Team

 

You received this message because you are subscribed to the Google Groups "oncokb-news" group.
To unsubscribe from this group and stop receiving emails from it, send an email to oncokb-news...@googlegroups.com.
To view this discussion on the web visit https://groups.google.com/d/msgid/oncokb-news/CAESvFs8z2wLG8G2cHmqZmp9mfb%2BvY9F539QDBWggHsUXHPthag%40mail.gmail.com.

 

 

=====================================================================

Please note that this e-mail and any files transmitted from
Memorial Sloan Kettering Cancer Center may be privileged, confidential,
and protected from disclosure under applicable law. If the reader of
this message is not the intended recipient, or an employee or agent
responsible for delivering this message to the intended recipient,
you are hereby notified that any reading, dissemination, distribution,
copying, or other use of this communication or any of its attachments
is strictly prohibited. If you have received this communication in
error, please notify the sender immediately by replying to this message
and deleting this message, any attachments, and all copies and backups
from your computer.

Disclaimer ID:MSKCC